Effect of therapy with combined interferon and tauroursodeoxycholic acid in chronic hepatitis C: Biochemical and virologic evaluation

Current Therapeutic Research

Volumn 55, Issue 6, 1994, Pages 675-681

  Picciotto, Antonino ^a   Savarino, Vincenzo ^a   Bardellini, Enrico ^a   Borzone, Stefano ^a   Pireddu, Marinette ^a   Sinelli, Nicoletta ^a   Celle, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; TAUROURSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SUBCUTANEOUS DRUG ADMINISTRATION; VIROLOGY;

EID: 0028239932     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(05)80802-1     Document Type: Article

References (29)

1. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon A preliminary report
2. Treatment of chronic hepatitis C with recombinant interferon alpha. A multi-center randomized, controlled trial
3. Recombinant interferon alpha therapy for chronic hepatitis C. A, randomized, double blind, placebo-controlled trial
4. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B, posttransfusion hepatitis: No correlation of outcome to presence of hepatitis C virus antibodies
5. A randomized controlled trial of interferon alpha-2b as therapy for chronic non-A, non-B hepatitis
6. Therapy of chronic post-transfusion non-A, non-B heaptitis with interferon alpha-2b: Swedish exprience
7. Recombinant human interferon alpha-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial
8. One-year treatment of chronic non-A, non-B hepatitis with interferon alpha-2b
9. Prolonged treatment (18 months) of chronic hepatitis C with recombinant α-interferon in comparison with a control group
10. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
11. Randomised controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A non-B hepatitis
12. Lymphoblastoid α-interferon for chronic hepatitis C: A randomized controlled study
13. Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation fibrogenesis and viremia
14. Interferon therapy in chronic hepatitis C. Evaluation of a low dose maintenance schedule in responder patients
15. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial
16. Physico-chemical properties of bile salts (BS) determine their hepatoprotective or toxic effects
17. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: In vitro studies in rat hepatocytes and human erythrocytes
18. Taurine conjugation is necessary for the protective effect of ursodeoxycholate in taurolithocholate induced cholestasis
19. Osservazioni preliminari sull'impiego terapeutico del tauroursodesossicolato
20. Effetti dell'acido tauroursodesossicolico (TUDCA) sulla litiasi biliare colesterolica e sulla composizione degli acidi biliari nella bile
21. Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids
22. Effect of tauroursodeoxycholic acid on serum liver enzymes and dyspeptic symptoms in patients with chronic active hepatitis
23. Characterization of the terminal regions of hepatitis C viral RNA: Identification of conserved sequences in the 5′ untranslated region and poly (A) tails at the 3′ ends
24. The 5′-terminal sequence of the hepatitis C virus genome
25. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C
26. Persistent hepatitis C viraemia without liver disease
27. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins
28. Significance of IgM antibody to hepatitis C virus in patients with chronic hepatitis C
29. Infection of peripheral mononuclear blood cells by hepatitis C virus